For planned acquisitions or licensing, careful analysis of CMC factors ensures no problem areas are overlooked.
Developing comprehensive chemistry, manufacturing, and controls programs are crucial to the success of a drug product. For planned acquisitions or licensing, a careful analysis of these critical factors is vital to ensure no problem areas are overlooked. Strategies for carrying out an effective due diligence exercise are described
Read this article in BioPharm International’s Regulatory Sourcebook October 2020 eBook.
BioPharm International
eBook: Regulatory Sourcebook
October 2020
Pages: 42–44
When referring to this article, please cite it as W. Lambert, “Due Diligence Assessment of CMC Activities," BioPharm International Regulatory Sourcebook eBook (October 2020).
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.